ClinicalTrials.gg
CompletedNCT05656040Updated Sep 10, 2025Results posted

A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011)

A Phase 1 interventional study of MK-2060 and Placebo in End-Stage Renal Disease, End-Stage Kidney Disease and Kidney Failure, Chronic, sponsored by Merck Sharp & Dohme LLC. Completed at 4 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-10.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Kidney Failure, Chronic by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Kidney Failure, Chronic · Merck & Co., Inc.

Enrollment
9th of 12
14 · median 18
Started
2023
with 1 other
Phase 1
10 of 12
none open now
Registered
9th of 12
by date

Among the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc, this one is the 9th largest by enrollment, is one of 2 that started in 2023, is one of 10 in phase 1, and was the 9th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

None of the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc is open now. The open studies under Kidney Failure, Chronic, anywhere →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc as a file.
02

Study summary

This was intended as a three-part study of MK-2060 in participants with chronic and/or end-stage kidney disease (Parts 2 and 3 were not initiated due to reasons not related to safety). The purpose of Part 1 of the study was to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single subcutaneous dose of MK-2060 in stage 4 chronic kidney disease (CKD4) [Part2 was intended to evaluate multiple subcutaneous doses in CKD4 participants and Part 3 was intended to evaluate a single subcutaneous dose of MK-2060 in participants with end-stage kidney disease (ESRD)]. The primary hypothesis for Part 1 was that the true geometric mean of the area under the concentration-time curve from 0 to infinity (AUC0-inf) after a single-dose of MK-2060 in adult CKD4 participants would be at least 11300 nM*hr.

03

Conditions studied

  • End-Stage Renal Disease
  • End-Stage Kidney Disease
  • Kidney Failure, Chronic
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At the time of screening, has stage 4 or 5 chronic kidney disease (Parts 1 and 2) or end-state kidney disease on peritoneal dialysis (Part 3).
  • Has a (BMI) ≥ 18 and ≤ 45 kg/m\^2.

Exclusion criteria

Exclusion Criteria:

  • Has a history of cancer, including adenocarcinoma, except adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix or other malignances which have been successfully treated ≥ 5 years prior to prestudy with appropriate follow-up.
  • Has a history of deep vein thrombosis or pulmonary embolism, a history of vascular access thrombosis within 1 month prior to enrollment, or has a personal or family history of bleeding disorder.
  • Has a history of gastrointestinal (GI) bleeding, duodenal polyps, or gastric ulcer in the last 5 years or severe hemorrhoidal bleed in the last 3 months.
  • Has a history of or current frequent epistaxis within the last 3 months or active gingivitis.
  • Has ongoing anticoagulant therapy or antiplatelet therapy. Aspirin is permitted.
  • Has planned significant dental procedures at the time of screening or pre-dose or other planned surgical procedures within duration of participation of study.
  • Is positive for surface antigen or (HIV).
  • Has had major surgery and/or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the pre-study visit.
  • Has a history (participant recall) of receiving any human immunoglobulin preparation such as intravenous immunoglobulin (IVIG) or RhoGAM within the last year.
  • Has a history (participant recall) of receiving any biological therapy (including human blood products or monoclonal antibodies; excluding erythropoietin and insulin) within the last 3 months or vaccination within the last 1 month, except the seasonal flu and pneumococcal vaccine or COVID-19 vaccine.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    MK-2060 30 mg

    Participants received MK-2060 30 mg administered as a single subcutaneous dose on Day 1.

    Biological: MK-2060

  • Placebo comparator
    Placebo

    Participants received placebo (normal saline) administered as a single subcutaneous dose on Day 1.

    Drug: Placebo

Interventions

  • BiologicalMK-2060

    MK-2060 lyophilized powder diluted in normal saline and administered subcutaneously

  • DrugPlacebo

    Normal saline administered subcutaneously

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants Who Experience One or More Bleeding Related Adverse Events (AE)

    Bleeding related AEs will include any sign or symptom of bleeding, even if not requiring intervention by a medical/healthcare professional, as well as clinically relevant nonmajor bleeding or major bleeding.

    Time frame: Up to approximately 104 days

  2. Part 2: Number of Participants Who Experience One or More Bleeding Related AEs

    Bleeding related AEs include any sign or symptom of bleeding, even if not requiring intervention by a medical/healthcare professional, as well as clinically relevant nonmajor bleeding or major bleeding.

    Time frame: Up to approximately 144 days

  3. Part 3: Number of Participants Who Experience One or More Bleeding Related AEs

    Bleeding related AEs will include any sign or symptom of bleeding, even if not requiring intervention by a medical/healthcare professional, as well as clinically relevant nonmajor bleeding or major bleeding.

    Time frame: Up to approximately 104 days

  4. Part 1: Number of Participants Who Experience One or More AEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 104 days

  5. Part 2: Number of Participants Who Experience One or More AEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 144 days

  6. Part 3: Number of Participants Who Experience One or More AEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 104 days

  7. Part 1: Number of Participants Who Discontinue Study Treatment to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 104 days

  8. Part 2: Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 144 days

  9. Part 3: Number of Participants Who Discontinue Study Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 104 days

  10. Part 1: Area Under the Concentration-Time Curve From 0 to Infinity (AUC0-inf) of MK-2060

    Blood was collected to determine the AUC0-inf of MK-2060 in plasma.

    Time frame: Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 60, and 90 post-dose

  11. Part 2: AUC0-inf of MK-2060

    Blood was to be collected at pre-specified time points to determine the AUC0-inf of MK-2060 in plasma.

    Time frame: Days 1, 2, 4, 8, 15, and 22: pre-dose; once daily on Days 10, 17, 26, 29, 35, 42, 49, 63, 81, 111, and 130 post-dose

  12. Part 3: AUC0-inf of MK-2060

    Blood was to be collected at pre-specified time points to determine the AUC0-inf of MK-2060 in plasma.

    Time frame: Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 42, 60, 90, and 120 post-dose

  13. Part 1: Area Under the Concentration-Time Curve From Time 0 to 168 Hours (AUC0-168) of MK-2060

    Blood was collected to determine the AUC0-168 of MK-2060 in plasma.

    Time frame: Pre-dose, 1, 12, 24, 48, 120, and 168 hours post-dose

  14. Part 2: AUC0-168 of MK-2060

    Blood was to be collected at pre-specified time points to determine the AUC0-168 of MK-2060 in plasma from 0 to 168 hours.

    Time frame: Pre-dose, 24, 72, and 168 hours post-dose

  15. Part 3: AUC0-168 of MK-2060

    Blood was to be collected at pre-specified time points to determine the AUC0-168 of MK-2060 in plasma from 0 to 168 hours.

    Time frame: Pre-dose, 1, 12, 24, 48, 120, and 168 hours post-dose

  16. Part 1: Maximum Plasma Concentration (Cmax) of MK-2060

    Blood was collected at pre-specified time points to determine the Cmax of MK-2060 in plasma.

    Time frame: Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 60, and 90 post-dose

  17. Part 2: Cmax of MK-2060

    Blood was to be collected at pre-specified time points to determine the Cmax of MK-2060 in plasma.

    Time frame: Days 1, 2, 4, 8, 15, and 22: pre-dose; once daily on Days 10, 17, 26, 29, 35, 42, 49, 63, 81, 111, and 130 post-dose

  18. Part 3: Cmax of MK-2060

    Blood was to be collected at pre-specified time points to determine the Cmax of MK-2060 in plasma.

    Time frame: Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 42, 60, 90, and 120 post-dose

  19. Part 1: Plasma Concentration at 168 Hours (C168) of MK-2060

    Blood was collected at 168 hours post-dose to determine the C168 of MK-2060 in plasma.

    Time frame: 168 hours post-dose

  20. Part 2: C168 of MK-2060

    Blood was to be collected at 168 hours post-dose to determine the C168 of MK-2060 in plasma.

    Time frame: 168 hours post-dose

  21. Part 3: C168 of MK-2060

    Blood was to be collected at 168 hours post-dose to determine the C168 of MK-2060 in plasma.

    Time frame: 168 hours post-dose

  22. Part 1: Time to Maximum Plasma Concentration (Tmax) of MK-2060

    Blood was collected at pre-specified time points to determine the Tmax of MK-2060 in plasma.

    Time frame: Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 60, and 90 post-dose

  23. Part 2: Tmax of MK-2060

    Blood was to be collected at pre-specified time points to determine the Tmax of MK-2060 in plasma.

    Time frame: Days 1, 2, 4, 8, 15, and 22: pre-dose; once daily on Days 10, 17, 26, 29, 35, 42, 49, 63, 81, 111, and 130 post-dose

  24. Part 3: Tmax of MK-2060

    Blood was to be collected at pre-specified time points to determine the Tmax of MK-2060 in plasma.

    Time frame: Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 42, 60, 90, and 120 post-dose

  25. Part 1: Terminal Half Life (t1/2) of MK-2060

    Blood was collected at pre-specified time points to determine the terminal t1/2 of MK-2060 in plasma.

    Time frame: Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 60, and 90 post-dose

  26. Part 2: t1/2 of MK-2060

    Blood was to be collected at pre-specified time points to determine the terminal t1/2 of MK-2060 in plasma.

    Time frame: Days 1, 2, 4, 8, 15, and 22: pre-dose; once daily on Days 10, 17, 26, 29, 35, 42, 49, 63, 81, 111, and 130 post-dose

  27. Part 3: t1/2 of MK-2060

    Blood was to be collected at pre-specified time points to determine the terminal t1/2 of MK-2060 in plasma.

    Time frame: Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 42, 60, 90, and 120 post-dose

  28. Part 1: Apparent Total Clearance (CL/F) of MK-2060

    Blood was collected at pre-specified time points to determine the CL/F of MK-2060 in plasma.

    Time frame: Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 60, and 90 post-dose

  29. Part 2: CL/F of MK-2060

    Blood was to be collected at pre-specified time points to determine the CL/F of MK-2060 in plasma.

    Time frame: Days 1, 2, 4, 8, 15, and 22: pre-dose; once daily on Days 10, 17, 26, 29, 35, 42, 49, 63, 81, 111, and 130 post-dose

  30. Part 3: CL/F of MK-2060

    Blood was to be collected at pre-specified time points to determine the CL/F of MK-2060 in plasma.

    Time frame: Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 42, 60, 90, and 120 post-dose

  31. Part 1: Apparent Volume of Distribution (Vz/F) of MK-2060

    Blood was collected at pre-specified time points to determine the Vz/F of MK-2060 in plasma

    Time frame: Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 60, and 90 post-dose

  32. Part 2: Vz/F of MK-2060

    Blood was to be collected at pre-specified time points to determine the Vz/F of MK-2060 in plasma

    Time frame: Days 1, 2, 4, 8, 15, and 22: pre-dose; once daily on Days 10, 17, 26, 29, 35, 42, 49, 63, 81, 111, and 130 post-dose

  33. Part 3: Vz/F of MK-2060

    Blood was to be collected at pre-specified time points to determine the Vz/F of MK-2060 in plasma

    Time frame: Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 42, 60, 90, and 120 post-dose

Secondary outcomes

  1. Part 1: Mean Fold Change From Baseline in Activated Partial Thromboplastin Time (aPTT) of MK-2060

    Blood was collected at pre-specified time points to determine the aPTT of MK-2060 in plasma. Positive and negative scores indicate increases and decreases, respectively, in aPTT compared to baseline.

    Time frame: Day 1 (1 hr and 12 hrs postdose) and Days 2, 3, 6, 8, 11, 14, 21, 28, 60, and Post Study (Day 90)

  2. Part 2: Percent Change From Baseline in aPTT of MK-2060

    Blood was to be collected at pre-specified time points to determine the aPTT of MK-2060 in plasma.

    Time frame: Day 1 (1 hr and 12 hrs postdose) and Days 2, 3, 6, 8, 11, 14, 21, 28, 60, and Post Study (Day 90)

  3. Part 3: Percent Change From Baseline in aPTT of MK-2060

    Blood was to be collected at pre-specified time points to determine the aPTT of MK-2060 in plasma.

    Time frame: Day 1 (1 hr and 12 hrs postdose) and Days 2, 3, 6, 8, 11, 14, 21, 28, 60, and Post Study (Day 90)

07

Results

Posted Sep 10, 2025

Participant flow

Adult participants with stage 4 chronic kidney disease (CKD4) were recruited.

Participant flow — Overall Study
MilestoneMK-2060 30 mgPlacebo
Started113
Completed113
Not completed00

Outcome measures

PrimaryPart 1: Number of Participants Who Experience One or More Bleeding Related Adverse Events (AE)

Bleeding related AEs will include any sign or symptom of bleeding, even if not requiring intervention by a medical/healthcare professional, as well as clinically relevant nonmajor bleeding or major bleeding.

Time frame:
Up to approximately 104 days
Reported as:
Count of participants · Participants
Part 1: Number of Participants Who Experience One or More Bleeding Related Adverse Events (AE)
ParticipantsMK-2060 30 mgPlacebo
Part 1: Number of Participants Who Experience One or More Bleeding Related Adverse Events (AE)00
PrimaryPart 2: Number of Participants Who Experience One or More Bleeding Related AEs

Bleeding related AEs include any sign or symptom of bleeding, even if not requiring intervention by a medical/healthcare professional, as well as clinically relevant nonmajor bleeding or major bleeding.

Time frame:
Up to approximately 144 days

No measurements were reported for this outcome.

PrimaryPart 3: Number of Participants Who Experience One or More Bleeding Related AEs

Bleeding related AEs will include any sign or symptom of bleeding, even if not requiring intervention by a medical/healthcare professional, as well as clinically relevant nonmajor bleeding or major bleeding.

Time frame:
Up to approximately 104 days

No measurements were reported for this outcome.

PrimaryPart 1: Number of Participants Who Experience One or More AEs

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Time frame:
Up to approximately 104 days
Reported as:
Count of participants · Participants
Part 1: Number of Participants Who Experience One or More AEs
ParticipantsMK-2060 30 mgPlacebo
Part 1: Number of Participants Who Experience One or More AEs52
PrimaryPart 2: Number of Participants Who Experience One or More AEs

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Time frame:
Up to approximately 144 days

No measurements were reported for this outcome.

PrimaryPart 3: Number of Participants Who Experience One or More AEs

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Time frame:
Up to approximately 104 days

No measurements were reported for this outcome.

PrimaryPart 1: Number of Participants Who Discontinue Study Treatment to an AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Time frame:
Up to approximately 104 days
Reported as:
Count of participants · Participants
Part 1: Number of Participants Who Discontinue Study Treatment to an AE
ParticipantsMK-2060 30 mgPlacebo
Part 1: Number of Participants Who Discontinue Study Treatment to an AE00
PrimaryPart 2: Number of Participants Who Discontinue Study Treatment Due to an AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Time frame:
Up to approximately 144 days

No measurements were reported for this outcome.

PrimaryPart 3: Number of Participants Who Discontinue Study Due to an AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Time frame:
Up to approximately 104 days

No measurements were reported for this outcome.

PrimaryPart 1: Area Under the Concentration-Time Curve From 0 to Infinity (AUC0-inf) of MK-2060

Blood was collected to determine the AUC0-inf of MK-2060 in plasma.

Time frame:
Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 60, and 90 post-dose
Reported as:
Geometric mean · hr*nM
Part 1: Area Under the Concentration-Time Curve From 0 to Infinity (AUC0-inf) of MK-2060
hr*nMMK-2060 30 mgPlacebo
Part 1: Area Under the Concentration-Time Curve From 0 to Infinity (AUC0-inf) of MK-206014300 ± 40.9—
PrimaryPart 2: AUC0-inf of MK-2060

Blood was to be collected at pre-specified time points to determine the AUC0-inf of MK-2060 in plasma.

Time frame:
Days 1, 2, 4, 8, 15, and 22: pre-dose; once daily on Days 10, 17, 26, 29, 35, 42, 49, 63, 81, 111, and 130 post-dose

No measurements were reported for this outcome.

PrimaryPart 3: AUC0-inf of MK-2060

Blood was to be collected at pre-specified time points to determine the AUC0-inf of MK-2060 in plasma.

Time frame:
Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 42, 60, 90, and 120 post-dose

No measurements were reported for this outcome.

PrimaryPart 1: Area Under the Concentration-Time Curve From Time 0 to 168 Hours (AUC0-168) of MK-2060

Blood was collected to determine the AUC0-168 of MK-2060 in plasma.

Time frame:
Pre-dose, 1, 12, 24, 48, 120, and 168 hours post-dose
Reported as:
Geometric mean · hr*nM
Part 1: Area Under the Concentration-Time Curve From Time 0 to 168 Hours (AUC0-168) of MK-2060
hr*nMMK-2060 30 mgPlacebo
Part 1: Area Under the Concentration-Time Curve From Time 0 to 168 Hours (AUC0-168) of MK-2060727 ± 103.3—
PrimaryPart 2: AUC0-168 of MK-2060

Blood was to be collected at pre-specified time points to determine the AUC0-168 of MK-2060 in plasma from 0 to 168 hours.

Time frame:
Pre-dose, 24, 72, and 168 hours post-dose

No measurements were reported for this outcome.

PrimaryPart 3: AUC0-168 of MK-2060

Blood was to be collected at pre-specified time points to determine the AUC0-168 of MK-2060 in plasma from 0 to 168 hours.

Time frame:
Pre-dose, 1, 12, 24, 48, 120, and 168 hours post-dose

No measurements were reported for this outcome.

PrimaryPart 1: Maximum Plasma Concentration (Cmax) of MK-2060

Blood was collected at pre-specified time points to determine the Cmax of MK-2060 in plasma.

Time frame:
Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 60, and 90 post-dose
Reported as:
Geometric mean · nM
Part 1: Maximum Plasma Concentration (Cmax) of MK-2060
nMMK-2060 30 mgPlacebo
Part 1: Maximum Plasma Concentration (Cmax) of MK-206011.3 ± 38.8—
PrimaryPart 2: Cmax of MK-2060

Blood was to be collected at pre-specified time points to determine the Cmax of MK-2060 in plasma.

Time frame:
Days 1, 2, 4, 8, 15, and 22: pre-dose; once daily on Days 10, 17, 26, 29, 35, 42, 49, 63, 81, 111, and 130 post-dose

No measurements were reported for this outcome.

PrimaryPart 3: Cmax of MK-2060

Blood was to be collected at pre-specified time points to determine the Cmax of MK-2060 in plasma.

Time frame:
Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 42, 60, 90, and 120 post-dose

No measurements were reported for this outcome.

PrimaryPart 1: Plasma Concentration at 168 Hours (C168) of MK-2060

Blood was collected at 168 hours post-dose to determine the C168 of MK-2060 in plasma.

Time frame:
168 hours post-dose
Reported as:
Geometric mean · nM
Part 1: Plasma Concentration at 168 Hours (C168) of MK-2060
nMMK-2060 30 mgPlacebo
Part 1: Plasma Concentration at 168 Hours (C168) of MK-20607.19 ± 79.7—
PrimaryPart 2: C168 of MK-2060

Blood was to be collected at 168 hours post-dose to determine the C168 of MK-2060 in plasma.

Time frame:
168 hours post-dose

No measurements were reported for this outcome.

PrimaryPart 3: C168 of MK-2060

Blood was to be collected at 168 hours post-dose to determine the C168 of MK-2060 in plasma.

Time frame:
168 hours post-dose

No measurements were reported for this outcome.

PrimaryPart 1: Time to Maximum Plasma Concentration (Tmax) of MK-2060

Blood was collected at pre-specified time points to determine the Tmax of MK-2060 in plasma.

Time frame:
Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 60, and 90 post-dose
Reported as:
Median · hours
Part 1: Time to Maximum Plasma Concentration (Tmax) of MK-2060
hoursMK-2060 30 mgPlacebo
Part 1: Time to Maximum Plasma Concentration (Tmax) of MK-2060312.82 (143.67 to 648.88)—
PrimaryPart 2: Tmax of MK-2060

Blood was to be collected at pre-specified time points to determine the Tmax of MK-2060 in plasma.

Time frame:
Days 1, 2, 4, 8, 15, and 22: pre-dose; once daily on Days 10, 17, 26, 29, 35, 42, 49, 63, 81, 111, and 130 post-dose

No measurements were reported for this outcome.

PrimaryPart 3: Tmax of MK-2060

Blood was to be collected at pre-specified time points to determine the Tmax of MK-2060 in plasma.

Time frame:
Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 42, 60, 90, and 120 post-dose

No measurements were reported for this outcome.

PrimaryPart 1: Terminal Half Life (t1/2) of MK-2060

Blood was collected at pre-specified time points to determine the terminal t1/2 of MK-2060 in plasma.

Time frame:
Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 60, and 90 post-dose
Reported as:
Geometric mean · hours
Part 1: Terminal Half Life (t1/2) of MK-2060
hoursMK-2060 30 mgPlacebo
Part 1: Terminal Half Life (t1/2) of MK-2060677 ± 26.3—
PrimaryPart 2: t1/2 of MK-2060

Blood was to be collected at pre-specified time points to determine the terminal t1/2 of MK-2060 in plasma.

Time frame:
Days 1, 2, 4, 8, 15, and 22: pre-dose; once daily on Days 10, 17, 26, 29, 35, 42, 49, 63, 81, 111, and 130 post-dose

No measurements were reported for this outcome.

PrimaryPart 3: t1/2 of MK-2060

Blood was to be collected at pre-specified time points to determine the terminal t1/2 of MK-2060 in plasma.

Time frame:
Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 42, 60, 90, and 120 post-dose

No measurements were reported for this outcome.

PrimaryPart 1: Apparent Total Clearance (CL/F) of MK-2060

Blood was collected at pre-specified time points to determine the CL/F of MK-2060 in plasma.

Time frame:
Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 60, and 90 post-dose
Reported as:
Geometric mean · Liters/hour
Part 1: Apparent Total Clearance (CL/F) of MK-2060
Liters/hourMK-2060 30 mgPlacebo
Part 1: Apparent Total Clearance (CL/F) of MK-20600.0141 ± 40.9—
PrimaryPart 2: CL/F of MK-2060

Blood was to be collected at pre-specified time points to determine the CL/F of MK-2060 in plasma.

Time frame:
Days 1, 2, 4, 8, 15, and 22: pre-dose; once daily on Days 10, 17, 26, 29, 35, 42, 49, 63, 81, 111, and 130 post-dose

No measurements were reported for this outcome.

PrimaryPart 3: CL/F of MK-2060

Blood was to be collected at pre-specified time points to determine the CL/F of MK-2060 in plasma.

Time frame:
Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 42, 60, 90, and 120 post-dose

No measurements were reported for this outcome.

PrimaryPart 1: Apparent Volume of Distribution (Vz/F) of MK-2060

Blood was collected at pre-specified time points to determine the Vz/F of MK-2060 in plasma

Time frame:
Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 60, and 90 post-dose
Reported as:
Geometric mean · Liters
Part 1: Apparent Volume of Distribution (Vz/F) of MK-2060
LitersMK-2060 30 mgPlacebo
Part 1: Apparent Volume of Distribution (Vz/F) of MK-206013.8 ± 39.6—
PrimaryPart 2: Vz/F of MK-2060

Blood was to be collected at pre-specified time points to determine the Vz/F of MK-2060 in plasma

Time frame:
Days 1, 2, 4, 8, 15, and 22: pre-dose; once daily on Days 10, 17, 26, 29, 35, 42, 49, 63, 81, 111, and 130 post-dose

No measurements were reported for this outcome.

PrimaryPart 3: Vz/F of MK-2060

Blood was to be collected at pre-specified time points to determine the Vz/F of MK-2060 in plasma

Time frame:
Day 1: pre-dose, 1 and 12 hours post-dose; once daily on Days 2, 3, 6, 8, 11, 14, 21, 28, 42, 60, 90, and 120 post-dose

No measurements were reported for this outcome.

SecondaryPart 1: Mean Fold Change From Baseline in Activated Partial Thromboplastin Time (aPTT) of MK-2060

Blood was collected at pre-specified time points to determine the aPTT of MK-2060 in plasma. Positive and negative scores indicate increases and decreases, respectively, in aPTT compared to baseline.

Time frame:
Day 1 (1 hr and 12 hrs postdose) and Days 2, 3, 6, 8, 11, 14, 21, 28, 60, and Post Study (Day 90)
Reported as:
Mean · Mean fold change from baseline
Part 1: Mean Fold Change From Baseline in Activated Partial Thromboplastin Time (aPTT) of MK-2060
Mean fold change from baselineMK-2060 30 mgPlacebo
Day 1: 1 Hour Postdose1.047 ± 0.0280.977 ± 0.037
Day 1: 12 Hours Postdose1.044 ± 0.030.994 ± 0.017
Day 21.05 ± 0.0210.971 ± 0.02
Day 31.137 ± 0.041.032 ± 0.033
Day 61.219 ± 0.0591.075 ± 0.081
Day 81.202 ± 0.0591.08 ± 0.093
Day 111.157 ± 0.0631.08 ± 0.084
Day 141.128 ± 0.0421.102 ± 0.114
Day 211.114 ± 0.0371.01 ± 0.075
Day 281.07 ± 0.0481.012 ± 0.049
Day 601.101 ± 0.0381.053 ± 0.115
Post Study (Day 90)1.026 ± 0.0441.129 ± 0.064
SecondaryPart 2: Percent Change From Baseline in aPTT of MK-2060

Blood was to be collected at pre-specified time points to determine the aPTT of MK-2060 in plasma.

Time frame:
Day 1 (1 hr and 12 hrs postdose) and Days 2, 3, 6, 8, 11, 14, 21, 28, 60, and Post Study (Day 90)

No measurements were reported for this outcome.

SecondaryPart 3: Percent Change From Baseline in aPTT of MK-2060

Blood was to be collected at pre-specified time points to determine the aPTT of MK-2060 in plasma.

Time frame:
Day 1 (1 hr and 12 hrs postdose) and Days 2, 3, 6, 8, 11, 14, 21, 28, 60, and Post Study (Day 90)

No measurements were reported for this outcome.

Adverse events

Collected over Up to approximately 104 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MK-2060 30 mg0/11 (0%)2/11 (18.2%)5/11 (45.5%)
Placebo0/3 (0%)0/3 (0%)2/3 (66.7%)
Most frequent serious events
Most frequent serious events
EventMK-2060 30 mgPlacebo
AnaemiaBlood and lymphatic system disorders1/110/3
Cardiac failure congestiveCardiac disorders1/110/3
Acute kidney injuryRenal and urinary disorders1/110/3
Most frequent other events
Showing 10 of 16
Most frequent other events
EventMK-2060 30 mgPlacebo
Eustachian tube obstructionEar and labyrinth disorders0/111/3
Occult blood positiveInvestigations0/111/3
White blood cell count increasedInvestigations0/111/3
Vertigo positionalEar and labyrinth disorders1/110/3
Abdominal painGastrointestinal disorders1/110/3
NauseaGastrointestinal disorders1/110/3
VomitingGastrointestinal disorders1/110/3
AstheniaGeneral disorders1/110/3
Injection site erythemaGeneral disorders1/110/3
Respiratory tract infectionInfections and infestations1/110/3

Baseline characteristics

Age, Continuous
Age, Continuous(Years)MK-2060 30 mgPlaceboTotal
Mean71.1 ± 9.459.0 ± 17.468.5 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)MK-2060 30 mgPlaceboTotal
Female729
Male415
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MK-2060 30 mgPlaceboTotal
Hispanic or Latino112
Not Hispanic or Latino10212
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MK-2060 30 mgPlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American606
White538
More than one race000
Unknown or Not Reported000
08

Study locations

4 sites
  • Velocity Clinical Research, New Smyrna Beach ( Site 0003)
    Edgewater, Florida 32132, United States
  • Advanced Pharma CR, LLC ( Site 0006)
    Miami, Florida 33147, United States
  • Genesis Clinical Research, LLC ( Site 0004)
    Tampa, Florida 33603, United States
  • Alliance for Multispecialty Research, LLC ( Site 0002)
    Knoxville, Tennessee 37920, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Aug 2024, 18 months.

Results were first posted in Sep 2025, 1 year after primary completion.

Of 46 industry-sponsored phase 1 interventional studies under Kidney Failure, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 18 months is above that.

Counting every sponsor, half of 67 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2022
First posted
Dec 19, 2022
StartActual
Feb 8, 2023
Primary completionActual
Aug 12, 2024
CompletionActual
Aug 12, 2024
Results first posted
Sep 10, 2025
Last update
Sep 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05656040
Responsible party
Sponsor
First posted
Dec 19, 2022
Start date
Feb 8, 2023
Primary completion
Aug 12, 2024
Completion
Aug 12, 2024
Results posted
Sep 10, 2025
Last update
Sep 10, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-2060

Start the discussion